China is the second-largest medical device market on the planet, and it keeps growing while most Western markets flatten. The demand is real: an aging population, rising incomes, more chronic disease, hospitals upgrading their equipment. But I need to be honest with you from the first line. This is not a market you sell into. It is a market you get registered into, then get procured into, then get trusted into. Miss one of those three and your product never reaches a patient. This guide covers the real access path in 2026: NMPA registration with actual timelines and costs, the “Buy China” and localization rules that now decide public tenders, the volume-based procurement that crushes margins on some devices, and the B2B marketing that actually generates qualified leads in China today.
Written by Olivier Verot, founder of GMA, based in Shanghai since 2012. I have spent more than a decade helping foreign medical device, IVD and healthcare brands get found by Chinese hospitals, distributors and procurement officers. This article is the version of the market-access conversation I have with device makers every week.
China’s Medical Device Market in 2026: Big, Growing, and Tightly Framed
A market measured in trillions of yuan
Chinese analysts project the domestic medical device market at 1.7 to 1.9 trillion yuan for 2026, growing at a compound annual rate of 12 to 15 percent. That is well above the global average of 5 to 6 percent. Growth is not evenly spread. High-value consumables are expected to reach about 205.5 billion yuan in 2026, up from roughly 195.7 billion in 2025, and cardiovascular intervention plus orthopedic implants together approach 300 billion yuan with growth above 15 percent a year. Government demand is a big engine here: the 2026 large-scale equipment renewal program pushes county-level hospitals to replace old machines, which opens real budget for imaging, monitoring and diagnostics.
The reason this matters for a foreign brand: the money is concentrated in high-end and high-tech segments where domestic manufacturers still cannot fully compete. In 2025, imported devices still accounted for 6,040 approved registrations, about 42.6 percent of all NMPA approvals. Chinese hospitals still buy foreign when they need precision, reliability and clinical evidence. That is your window. It is a narrower window than it was five years ago, and it closes a little more every year, which is exactly why the access path has to be handled correctly.
Two markets, not one
China’s medical device market splits into two clear tiers, and this has not changed, it has hardened:
- Domestic manufacturers supplying low to mid-range products. Over 80 percent of Chinese device companies sit here. They are consolidating fast, buying up smaller players, and climbing into mid-tech niches they could not touch a decade ago.
- Foreign-sourced high-end products from the big multinationals and specialized mid-cap innovators. This is where imports still win, in advanced imaging, interventional cardiology, robotic surgery, high-end IVD and implants that need long clinical track records.
The policy direction is explicit. Under “Made in China 2025,” the target is for county hospitals to source 70 percent domestic high-end devices by 2025 and 95 percent by 2030. Read that again if you sell imported equipment. The public system is being steered, on purpose, toward local suppliers. That does not mean you are locked out. It means you need to understand exactly where the door is still open and how to walk through it.
Where the best opportunities still sit
The strongest prospects for foreign devices in 2026:
- In vitro diagnostics: high-end analyzers, specialty reagents, molecular diagnostics and point-of-care testing.
- Advanced imaging: high-field MRI, high-slice CT, and the software and AI layers on top of them.
- Interventional and implantable materials: complex stents, structural heart devices, high-spec orthopedic and spinal systems.
- Surgical robotics, energy-based surgical systems and anesthesia platforms.
- Rehabilitation, home-care monitoring and connected devices for chronic disease, riding the aging population.
NMPA Registration: The Gate You Cannot Skip
No device is sold legally in China without NMPA registration. This is the National Medical Products Administration, the Chinese equivalent of the FDA. Foreign companies routinely underestimate this step. They budget for marketing before they have a registration certificate, then discover the product cannot even be quoted to a hospital yet. Get the sequence right.
Classes I, II and III
- Class I (low risk, such as basic instruments and bandages): filing/record only, handled at provincial level, usually a few months.
- Class II (moderate risk, such as many monitors and diagnostic equipment): NMPA technical review runs around eight months of pure review time. With testing and documentation, plan 16 to 20 months end to end.
- Class III (high risk, such as implants, life-support and advanced imaging): review time around nine months, and the full journey commonly runs 20 to 26 months once type testing and, where required, local clinical work are included.
On cost, official government registration fees for imported Class II and Class III devices land roughly in the 30,000 to 43,000 US dollar range per product family, and China sits among the most expensive countries for these fees. Add type testing, translation, an in-country agent and consultancy, and a realistic Class III budget is well into six figures before your first sale. There is some relief: the 2025 Clinical Evaluation Exemption Catalogue added new product categories that skip the clinical evaluation report, and 39 updated registration guidelines took effect on 1 December 2025. A revised Good Manufacturing Practice for medical devices was published on 4 November 2025 and takes effect 1 November 2026, so you have a window to align your quality system.
One practical point people forget: every imported device needs a legal in-country agent in China who holds regulatory responsibility and post-market obligations. Choose that partner carefully, because switching agents later is painful. For the full regulatory picture, the NMPA 2025 registration data report is a solid reference on approval volumes and trends.
“Buy China,” Localization, and the Public Tender Reality
This is the part that changed most since this article first appeared, and it is the part that decides whether your registered product actually wins hospital business. China runs a “Buy China” procurement preference. Public buyers are directed to prioritize domestically produced devices. It is no longer a soft nudge.
On 6 July 2025, China’s Ministry of Finance issued a notice restricting EU-origin medical devices in government procurement. For any project with a device budget above 45 million yuan, roughly 6.3 million US dollars, EU companies are barred from bidding. For non-EU bidders, EU-imported content in the offer cannot exceed 50 percent of the contract value. The measure took effect immediately, exempting only tenders already awarded and cases where only an EU-imported device can meet the need. This was a retaliation move in a trade dispute, but the mechanism it uses, origin thresholds inside public tenders, is exactly the tool Chinese procurement can apply to any origin. You can read the official framing from China’s State Council.
What this means in plain terms. If your growth plan depends on large public hospital tenders, “imported” is increasingly a disadvantage on paper before anyone even looks at your specs. The counter-move that works is localization. Manufacturing or final assembly inside China, or a genuine joint venture, can reclassify your product as domestic for procurement purposes. Local production is no longer just a cost play, it is a market-access play. Many multinationals now run “in China, for China” lines specifically to stay eligible for public procurement. If full localization is too heavy, an OEM partnership, a technology license, or a strong distributor with local manufacturing can achieve part of the same effect.
Volume-Based Procurement (集采): The Margin Killer
If you sell high-value consumables, you have to understand centralized volume-based procurement, called 集采 in Chinese. The state pools demand across hospitals and provinces, then runs one giant tender. Winners get enormous volume. The price they accept is brutal.
The numbers are not subtle. Coronary stents fell from an average of around 13,000 yuan to roughly 700 yuan after the first national procurement, with follow-up rounds settling near 770 yuan. Orthopedic joint implants dropped about 83 percent, spinal implants about 84 percent. If your business model needs the old margins, VBP ends it overnight in the affected categories. The recent shift, from 2025 into 2026, is toward “stabilize price, improve quality.” The sixth national batch moved away from pure lowest-price logic and introduced a price-protection benchmark near 65 percent to stop destructive bidding, and factory-level prices in that round came down by an average of 20 percent or more rather than the 80 to 90 percent cuts of the early rounds.
My advice to device makers: know whether your category is already under 集采 or likely to enter it. If it is, either you compete on massive volume at thin margin with local production, or you position in the segments and premium tiers that VBP has not yet swallowed, backed by clinical differentiation. Do not build a China P&L on pre-VBP pricing for a consumable that procurement is clearly moving toward.
Digital: How Foreign Device Brands Actually Get Found in China
Registration and procurement decide if you can sell. Marketing decides if anyone knows you exist and trusts you when the tender or the distributor conversation happens. In a B2B medical context, the buyer is a hospital procurement officer, a department head, a KOL physician, or a distributor. They all do the same thing before they engage you: they search, and they check whether you are credible in Chinese. If you are invisible on Baidu and have no Chinese footprint, you look like a company that is not serious about China. That kills you before the first meeting.
1. A Chinese website is the non-negotiable foundation
Before any purchase or partnership, Chinese buyers check your official website. For a medical device, this site is where a hospital or distributor confirms you are real, registered and technically legitimate. Build it in Simplified Chinese, host it so it loads fast inside China, and put your regulatory status, clinical evidence, technical specs and reference sites front and center. A Chinese website also signals commitment. A brand with only an English site reads as a tourist. In the health field, where trust is everything, that impression alone loses deals.
2. E-reputation and clinical trust
Chinese buyers are cautious in healthcare for good reason. The market has seen scandals, and procurement officers protect themselves by checking your reputation across forums, Q&A portals, professional groups and official media. What they want is proof: peer-reviewed clinical data, real hospital references in China or comparable markets, regulatory certificates, and third-party coverage. Build that trust layer deliberately. Clinical evidence is not marketing fluff in this sector, it is the core of your credibility. The brands that win publish their data, name their reference hospitals, and make it easy to verify every claim.
Read also: best marketing practices for health firms in China
3. Baidu SEO on real buyer intent
Baidu is where the buying journey starts. The mistake foreign brands make is chasing generic vanity keywords. In B2B medical, you win by ranking on intent: the exact queries a procurement officer or distributor types when they are close to a decision. Think product category plus “厂家” (manufacturer), “代理” (distributor/agent), “价格” (price), “参数” (specifications), or a specific clinical application. Those searches have low volume and high value. Owning them puts you in front of people who are ready to talk.
Baidu is not Google. Its algorithm rewards content hosted in China, ICP-registered sites, and Chinese-language depth. SEO here is a slow build that compounds. SEM, the paid side, drives faster traffic but generally requires a Chinese business license and, for medical categories, extra qualification documents. For most foreign device brands, a strong organic Baidu presence plus targeted paid support is the right mix. If you want the mechanics, see our guide to the Baidu advertising network.
4. GEO: getting cited by DeepSeek and Doubao
A new behavior arrived fast. Chinese professionals now ask AI assistants, DeepSeek and ByteDance’s Doubao in particular, to shortlist suppliers and explain products. If those models do not know you, you are absent from a growing slice of the research phase. Generative Engine Optimization, GEO, is the practice of getting your brand into the answers these models give. The mechanism: publish clear, structured, factual Chinese content that states plainly what your device does, its clinical evidence, its NMPA status and its use cases, on sources these models ingest. Well-structured technical content, authoritative third-party mentions and consistent facts across the Chinese web raise the odds a model cites you. For a technical B2B device, this is a real early-mover advantage because most competitors have not started.
5. A professional WeChat account and private domain
WeChat is the backbone of B2B relationships in China. For a device company, the play is not consumer content, it is a professional service account plus a private domain. You build a WeChat official account that publishes clinical updates, application notes, congress recaps and regulatory news. Then you move real prospects, distributors, KOL physicians and procurement contacts, into WeChat groups and one-to-one chats managed by your local team. That private domain is where the relationship actually deepens. Every distributor negotiation, every technical question, every follow-up after a congress happens on WeChat. A brand with no WeChat presence is hard to even do business with here.
6. Medical congresses and specialized distributors
Do not let the digital focus fool you into skipping the offline core of this sector. Chinese medical congresses, national and provincial society meetings, are where KOL physicians, department heads and distributors gather. Presence there, a booth, a symposium, a KOL presenting your clinical data, builds the credibility that closes deals. The right specialized distributor is often the single most important decision you make. A good one already has the hospital relationships, the tender know-how and, increasingly, local logistics or assembly that help on the localization question. Pair the distributor’s relationships with your digital credibility, and the two reinforce each other. The distributor opens the door, your Baidu and WeChat presence makes the buyer comfortable walking through it.
7. KOL physicians and Xiaohongshu for the consumer-facing edge
In medical, the KOL is usually a respected doctor, professor or hospital. Their endorsement removes trust barriers the way nothing else does. The “guanxi” concept still holds: a recommendation from a credible clinician opens gateways. For devices with a patient-facing or clinic-facing side, home-care, aesthetics, dental, rehabilitation, hearing, Xiaohongshu (RED) now matters too. Patients research there before choosing a clinic or asking for a specific device. Doctors and clinics publish cases. The mechanism is different from Baidu: on Xiaohongshu, you win through authentic notes, real case content and clinic partnerships, not hard ads. If your device eventually reaches a consumer, being discoverable on Xiaohongshu shortens the path from patient awareness to clinic demand.
8. PR and e-commerce for the right products
Corporate news in Chinese health media still builds credibility with institutional buyers. A placement in a recognized health outlet is a trust signal a procurement officer notices. For device makers with a consumer product, home diagnostics, monitors, wellness devices, e-commerce is a genuine channel. JD.com is the platform most trusted for authentic products and the one we usually recommend first in health, with Tmall Global as the flagship option for leading brands. Just remember: e-commerce fits the consumer end of your range. It does not replace the registration, tender and distributor work that governs the hospital market.
Case Study: An Icelandic Device Maker Breaking Into China
Kristjan runs an Icelandic company that makes advanced rehabilitation and mobility devices, strong clinical evidence, a good name in Europe, almost no recognition in China. He came to us after a rough first attempt. His team had exhibited at one Shanghai trade show, collected a stack of business cards, and signed a distributor who then went quiet. Twelve months in, he had spent close to 120,000 euros and closed zero hospital orders. The distributor blamed “the market.” The real problems were concrete.
First, when Chinese buyers searched his product category on Baidu, he did not exist. No Chinese site, no content, nothing. To a procurement officer, he looked like a company testing the water, not committing. Second, his distributor had signed him for the exclusivity, not to actively sell, and had no incentive because Kristjan gave them nothing to work with, no Chinese materials, no clinical content in Mandarin, no lead flow. Third, one of his two flagship devices sat in a category that volume-based procurement had already compressed, so the margins his plan assumed were fiction.
What we changed. We built a Simplified Chinese site hosted in-country, focused on his regulatory status and clinical data, and ran Baidu SEO on narrow high-intent keywords tied to his device’s clinical application plus “厂家” and “代理.” We launched a professional WeChat account publishing his clinical evidence and rehab case studies, and used it to feed a private-domain group of physiotherapists and rehab-department contacts. We got him a symposium slot at a national rehabilitation congress with a Chinese KOL presenting his outcome data. And we repositioned his commercial focus onto the device that VBP had not touched, where his clinical edge justified a premium.
Why it worked: the buyers could finally find him, verify him in Chinese, and see a respected local clinician vouch for the evidence. That combination gave his distributor something real to sell, and gave two new distributors a reason to compete for territory. Inside nine months, Baidu was generating a steady flow of qualified distributor and hospital inquiries, the WeChat group had become his main channel for technical follow-up, and he closed his first three tier-2 and tier-3 hospital orders plus a second regional distributor. Not a hockey-stick miracle. A real base, built on being findable and credible instead of hoping one trade show would carry the whole China plan.
FAQ: China Medical Device Market Access
How long does NMPA registration take for an imported device?
Plan realistically. Class I is a filing that takes a few months. Class II runs about 16 to 20 months end to end, with roughly eight months of NMPA review time inside that. Class III commonly takes 20 to 26 months, since it can require type testing and local clinical evidence on top of a nine-month review. Start registration before you build your commercial plan, because you cannot legally quote a hospital without a certificate.
How much does registration cost?
Official government fees for imported Class II and Class III devices sit around 30,000 to 43,000 US dollars per product family, among the highest in the world. That is only the government fee. Add type testing, translation, an in-country agent, clinical work where required and consultancy, and a full Class III access budget usually runs into six figures before your first sale. Budget for the whole path, not just the filing.
Does “Buy China” mean imported devices are shut out of public hospitals?
Not shut out, disadvantaged. Public procurement is steered toward domestic products, and specific origin restrictions can bar or cap imports in large tenders, as the July 2025 measure on EU devices showed for projects above 45 million yuan. The workaround is localization: local manufacturing, assembly, a joint venture or an OEM arrangement that lets your product qualify as domestic. Imports still win in high-end segments where local options do not exist, but you should assume public tenders favor local and plan accordingly.
What is volume-based procurement and will it hit my product?
Volume-based procurement (集采) pools national demand into one tender in exchange for deep price cuts. It has slashed prices in categories like coronary stents (from about 13,000 to roughly 700 yuan) and orthopedic implants (down more than 80 percent). If your consumable is in or near a 集采 category, your margins will compress hard. Check your category’s status before you model your China P&L, and either commit to volume-at-low-margin with local production or focus on premium tiers VBP has not reached.
Do I really need Baidu SEO and WeChat for a B2B device?
Yes. Your buyers, procurement officers, department heads, distributors, KOL physicians, all research you online first. If Baidu shows nothing and you have no Chinese footprint, you look uncommitted and lose credibility before any meeting. Baidu SEO on high-intent keywords brings the qualified inquiries. WeChat is where the relationship and technical follow-up actually happen. Together they make your distributor’s job possible and your brand real to a cautious buyer.
Is a distributor enough, or do I need my own China presence?
A distributor is important but not sufficient on its own. Many foreign brands hand everything to a distributor, give them no Chinese marketing support, and wonder why nothing sells. The distributor opens hospital doors, but the buyer still checks you online and still needs Chinese-language clinical proof. Give your distributor a strong Chinese digital presence, WeChat content and lead flow to work with. The best results come from pairing a specialized distributor with your own brand credibility in Chinese.
How do AI answer engines like DeepSeek change medical device marketing?
Chinese professionals increasingly ask DeepSeek and Doubao to shortlist suppliers and explain products, which means some of the research phase now happens inside AI answers instead of on a results page. If these models do not know your device, you are missing from that shortlist. GEO, publishing clear, structured, factual Chinese content about your device, its evidence and its NMPA status on sources these models read, raises your odds of being cited. Few competitors have started, so it is an early-mover advantage for technical B2B brands.
Work With a Team That Knows Medical Access in China
GMA is a Shanghai-based agency that has helped medical device, IVD and healthcare brands get found, trusted and chosen by Chinese hospitals, distributors and procurement teams. We build your Chinese website and Baidu presence, run WeChat and GEO, connect you to KOL physicians and congresses, and align your digital work with the registration and localization realities of this market. If you want a clear read on where your device fits in the 2026 market, get in touch with our team.
- Ask us for the best market-access strategy for your device category.
- Request our white paper on health and medical marketing in China.
- Ask to see relevant case studies for your segment.
For related reading, see our guides to the pharmacy and healthcare export market in China, the medical tourism market in China, and PR in China.
